MyoVista wavECG vs Navina
A cardiology clinic reading 12-lead ECGs would buy HeartSciences, and a value-based primary care group chasing HCC capture would buy Navina. The vendors sell different products to different practices.
HeartSciences' MyoVista wavECG, a 12-lead resting electrocardiograph, received FDA 510(k) clearance K260005 on October 5, 2026. The clearance does not include an AI-ECG algorithm. The company says it does not intend to commercialize the device without a cleared algorithm, and its release gives no timeline. The site footer says its AI-ECG products are not commercially available in the United States, and the homepage links an Epic showroom listing. A business combination with Fortitude Mining Holdings, announced in June 2026, is pending.
On the Navina side, a VP in an unrated KLAS comment from August 2026 said it does a really good job on risk adjustment but is primarily focused on Medicare. Its homepage lists HCC recommendations at the point of care.
Decision support · Reviewed November 2, 2026
MyoVista wavECG
by HeartSciences
12-lead resting ECG device for cardiology clinics, FDA 510(k) cleared in October 2026 without its AI-ECG algorithm.
Navina
by Navina · founded 2018
AI copilot for chart review, risk adjustment and care gaps in primary care and value-based care groups.
When to pick each one
MyoVista wavECG
- 12-lead resting ECG for cardiology clinics
- Epic showroom listing linked on its homepage
- FDA 510(k) K260005, cleared October 5, 2026
Navina
- HCC suggestions at the point of care
- Risk adjustment praised in a KLAS comment
Score
Each row shows points earned of points available under the published rubric.
MyoVista wavECG
31of 100
Navina
36of 100
| Dimension | MyoVista wavECG | Navina | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 0 / 12 | +12 |
| HIPAA / SOC2 / BAA | 6 / 10 | 10 / 10 | -4 |
| EHR integrations (count) | 1.7 / 5.6 | 1.7 / 5.6 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 1.9 / 4.8 | 3.4 / 4.8 | -1.4 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 9 | 0 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
MyoVista wavECG
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Navina
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
MyoVista wavECG
FDA decisions
K260005 (opens in new tab)510(k)2026-10-05
MyoVista wavECG (DG-200-B15-003)
Navina
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | MyoVista wavECG | Navina |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Epic | athenahealth, Epic, Veradigm |
| Founded | n/a | 2018 |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.